Evidence map›Paper›PMID 42794737›Full record

ArticleInternational journal of molecular sciences2026

Genetic Variation in

Cristina Arqueros, Marta Andrés, Sònia Servitja, Júlia Giner, Ariadna Tibau, Maria Borrell, Sergio Martinez-Recio, Agustí Barnadas, Juliana Salazar

Abstract readMulticenter Study
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cristina ArquerosDepartment of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Marta AndrésDepartment of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0003-3214-1636
Sònia ServitjaSpanish Group for Breast Cancer Research (GEICAM), 08041 Barcelona, Spain.
Júlia GinerMedical Oncology Department, Corporació Sanitària Parc Taulí, 08208 Sabadell, Spain.ORCID 0009-0003-1672-0010
Ariadna TibauDepartment of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0003-0229-6987
Maria BorrellMedical Oncology Department, Vall d'Hebron Hospital, 08035 Barcelona, Spain.
Sergio Martinez-RecioDepartment of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0001-8056-7100
Agustí BarnadasDepartment of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0002-0429-1349
Juliana SalazarTranslational Medical Oncology Laboratory, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain.ORCID 0000-0002-3581-4499

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Palbociclib has shown survival benefits in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. At present, however, no genetic predictors of palbociclib-related hematological toxicity have been validated for clinical use. The aim of this study was to evaluate whether genetic variants are associated with palbociclib toxicity and patient prognosis. Multicenter study of 113 patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer treated with palbociclib plus endocrine therapy. Genotyping of DNA from blood samples was performed to determine 18 variants in seven target genes (

Indexed as

Antineoplastic AgentsBreast NeoplasmsGenetic VariationPiperazinesPregnane X ReceptorPyridinesAdultAgedFemaleHumansMiddle AgedPolymorphism, Single NucleotidePrognosisAntineoplastic AgentsNR1I2 protein, humanpalbociclibPiperazinesPregnane X ReceptorPyridinesHER2-negative advanced breast cancerHR-positiveNR1I2palbociclibpharmacogeneticssafetysurvival

Identifiers

PMID42794737
PMCPMC13607729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.